Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Peripheral Primitive Neuroectodermal Tumor: early-phase trial registry

2 of 3 indexed Peripheral Primitive Neuroectodermal Tumor trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Peripheral Primitive Neuroectodermal Tumor: 3 US clinical trials tracked, 2 recruiting.

Peripheral Primitive Neuroectodermal Tumor is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is ITM Solucin, running 1 of these trials.

Enrollment posture brief

Registry condition peripheral-primitive-neuroectodermal-tumor

OPEN 2 | RECR 67% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Peripheral Primitive Neu (th…67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Peripheral Primitive Neuroectodermal Tumor

Peripheral Primitive Neuroectodermal Tumor lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Peripheral Primitive Neuroectodermal Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Peripheral Primitive Neuroectodermal Tumor is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Peripheral Primitive Neuroectodermal Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

trabectedin Drug
1 trials
pharmacological study Other
1 trials
Lutetium Lu 177-Edotreotide Drug
1 trials
Amino Acid Solution Other
1 trials
FoundationOne Liquid CDx Other
1 trials

US sites by state

Facility locations filed on Peripheral Primitive Neuroectodermal Tumor trials. A trial with sites in several states counts in each.

Washington 2 trials
Tennessee 2 trials
Pennsylvania 2 trials
Ohio 2 trials
California 2 trials
Vermont 1 trials
Utah 1 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Peripheral Primitive Neuroectodermal Tumor page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Peripheral Primitive Neuroectodermal Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • ITM Solucin sponsors the most Peripheral Primitive Neuroectodermal Tumor trials on record, review their full trial history before evaluating a specific study. See ITM Solucin's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peripheral Primitive Neuroectodermal Tumor condition card totals 3 registered trials; most-linked intervention trabectedin; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.